BURLINGAME, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced management will present at the Cantor Fitzgerald Second Annual Healthcare Conference on July 12 at 11:45 a.m. EDT at Le Parker Meridien Hotel, New York.

A webcast of the presentation will be available live and for 30 days following the event. The webcast can be viewed at: Corvus Webcast @ Cantor Conference and on the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus lead product, CPI-444 is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with TECENTRIQ™ (atezolizumab), Genentech's investigational cancer immunotherapy. TECENTRIQ™ is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit www.corvuspharma.com.

Investor Contact:
Leiv Lea
Chief Financial Officer 
LLea@corvuspharma.com
650-900-4522

Media Contact:
Julie Normart, W2O Group
415-946-1087
jnormart@w2ogroup.com